Rituximab for rheumatoid arthritis-related interstitial lung disease: A systematic review and meta-analysis.

Tarun Krishna Boppana Tarun Krishna Boppana Karan Madan Anant Mohan Vijay Hadda Randeep Guleria

Published in: Archives of rheumatology (2024)

Treatment with rituximab in RA-ILD was associated with a significant improvement in %-predicted FVC, as well as stabilization or improvement in ILD after one year of treatment.

Keyphrases

interstitial lung disease
rheumatoid arthritis
systemic sclerosis
idiopathic pulmonary fibrosis
diffuse large b cell lymphoma
disease activity
combination therapy